RU2756506C2 - Галогензамещенное гетероциклическое соединение - Google Patents

Галогензамещенное гетероциклическое соединение Download PDF

Info

Publication number
RU2756506C2
RU2756506C2 RU2018109925A RU2018109925A RU2756506C2 RU 2756506 C2 RU2756506 C2 RU 2756506C2 RU 2018109925 A RU2018109925 A RU 2018109925A RU 2018109925 A RU2018109925 A RU 2018109925A RU 2756506 C2 RU2756506 C2 RU 2756506C2
Authority
RU
Russia
Prior art keywords
thiophen
amino
carbonyl
biphenyl
ethoxy
Prior art date
Application number
RU2018109925A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109925A (ru
RU2018109925A3 (fr
Inventor
Нориаки ИВАСЕ
Хироси НИСИДА
Макото ОКУДО
Масааки ИТО
Сигеюки КОНО
Масааки МАТОЯМА
Сигеру УСИЯМА
Эйдзи ОКАНАРИ
Хирофуми МАЦУНАГА
Кендзи НИСИКАВА
Томио Кимура
Original Assignee
Убе Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Убе Индастриз, Лтд. filed Critical Убе Индастриз, Лтд.
Publication of RU2018109925A publication Critical patent/RU2018109925A/ru
Publication of RU2018109925A3 publication Critical patent/RU2018109925A3/ru
Application granted granted Critical
Publication of RU2756506C2 publication Critical patent/RU2756506C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2018109925A 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение RU2756506C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012-286425 2012-12-28
JP2012286425 2012-12-28
JP2013097171 2013-05-02
JP2013-097171 2013-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015131139A Division RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Publications (3)

Publication Number Publication Date
RU2018109925A RU2018109925A (ru) 2019-02-27
RU2018109925A3 RU2018109925A3 (fr) 2020-12-03
RU2756506C2 true RU2756506C2 (ru) 2021-10-01

Family

ID=51021433

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018109925A RU2756506C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Country Status (13)

Country Link
US (2) US10000463B2 (fr)
EP (2) EP3360869B1 (fr)
JP (3) JP6176258B2 (fr)
KR (1) KR102189166B1 (fr)
CN (2) CN107698555B (fr)
AU (1) AU2013366898B2 (fr)
BR (1) BR112015015275B1 (fr)
CA (1) CA2896701C (fr)
DK (2) DK2940013T3 (fr)
ES (2) ES2667798T3 (fr)
MX (1) MX369801B (fr)
RU (2) RU2756506C2 (fr)
WO (1) WO2014104372A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698555B (zh) * 2012-12-28 2020-05-05 宇部兴产株式会社 卤素取代杂环化合物
EA033923B1 (ru) 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
CA2953472C (fr) * 2014-06-27 2022-08-02 Ube Industries, Ltd. Sel d'un compose heterocyclique substitue par un groupe halogeno
EP3378491A4 (fr) * 2015-11-20 2019-07-17 UBE Industries, Ltd. Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash)
WO2021020429A1 (fr) * 2019-07-30 2021-02-04 大正製薬株式会社 Composé d'urée pour antagoniser le récepteur lpa1
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
JP2023529369A (ja) 2020-06-03 2023-07-10 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニスト及びそれらの使用
CR20220609A (es) 2020-06-03 2023-05-04 Gilead Sciences Inc Antagonistas del receptor de lpa y usos de los mismos
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (fr) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (fr) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
WO2012138797A1 (fr) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. Composés à base de 3- ou 5-biphényl-4-ylisoxazole utiles pour le traitement de la fibrose, de la douleur, du cancer et de troubles respiratoires, allergiques, de troubles du système nerveux ou de troubles cardiovasculaires
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (fr) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
MX2011003383A (es) 2008-09-29 2011-04-21 Lilly Co Eli Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis.
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (fr) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011091167A2 (fr) 2010-01-22 2011-07-28 The General Hospital Corporation Ciblage du récepteur de l'acide lysophosphatidique pour sclérodermie et autres maladies fibrosantes
WO2011159635A1 (fr) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Antagoniste de récepteur d'acide lysophosphatidique pour le traitement d'affections dermiques
WO2011159633A1 (fr) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Formulations inhalables d'antagonistes de récepteur d'acide lysophosphatidique
US20130253019A1 (en) 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
EP2648726B1 (fr) 2010-12-07 2018-04-04 Amira Pharmaceuticals, Inc. Antagoniste lpa1 polycyclique et utilisations de celui-ci
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
CN107698555B (zh) * 2012-12-28 2020-05-05 宇部兴产株式会社 卤素取代杂环化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (fr) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (fr) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
WO2012138797A1 (fr) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. Composés à base de 3- ou 5-biphényl-4-ylisoxazole utiles pour le traitement de la fibrose, de la douleur, du cancer et de troubles respiratoires, allergiques, de troubles du système nerveux ou de troubles cardiovasculaires
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa

Also Published As

Publication number Publication date
DK2940013T3 (en) 2018-03-26
BR112015015275B1 (pt) 2021-12-14
RU2018109925A (ru) 2019-02-27
EP2940013A4 (fr) 2016-08-03
CN107698555A (zh) 2018-02-16
BR112015015275A2 (pt) 2017-07-11
US20150376160A1 (en) 2015-12-31
JP6176258B2 (ja) 2017-08-09
AU2013366898B2 (en) 2017-06-29
KR102189166B1 (ko) 2020-12-09
DK3360869T3 (da) 2020-10-12
CA2896701C (fr) 2020-10-06
ES2825031T3 (es) 2021-05-14
KR20150100756A (ko) 2015-09-02
AU2013366898A1 (en) 2015-08-13
BR112015015275A8 (pt) 2019-10-22
US10597375B2 (en) 2020-03-24
EP3360869B1 (fr) 2020-07-29
EP2940013B1 (fr) 2018-02-21
JP6569792B2 (ja) 2019-09-04
JP2019014739A (ja) 2019-01-31
WO2014104372A1 (fr) 2014-07-03
CN107698555B (zh) 2020-05-05
ES2667798T3 (es) 2018-05-14
CN104884447A (zh) 2015-09-02
US10000463B2 (en) 2018-06-19
RU2015131139A (ru) 2017-02-03
CN104884447B (zh) 2017-10-10
JPWO2014104372A1 (ja) 2017-01-19
MX369801B (es) 2019-11-21
EP2940013A1 (fr) 2015-11-04
JP2017214410A (ja) 2017-12-07
JP6414286B2 (ja) 2018-10-31
MX2015008479A (es) 2015-09-23
EP3360869A1 (fr) 2018-08-15
CA2896701A1 (fr) 2014-07-03
RU2649398C2 (ru) 2018-04-03
US20180258062A1 (en) 2018-09-13
RU2018109925A3 (fr) 2020-12-03

Similar Documents

Publication Publication Date Title
US10597375B2 (en) Halogen-substituted heterocyclic compound
US9382197B2 (en) Substituted hydroxamic acids and uses thereof
US8034832B2 (en) Gyrase inhibitors and uses thereof
US7074836B1 (en) Para-terphenyl compounds
US20100278733A1 (en) Composition for diagnosis of amyloid-related disease
RU2641895C2 (ru) ГЕТЕРОЦИКЛИЛЬНЫЕ ПИРИМИДИНОВЫЕ АНАЛОГИ В КАЧЕСТВЕ ИНГИБИТОРОВ Tук2
EP3330256B1 (fr) DÉRIVÉ HÉTÉROCYCLIQUE À ACTIVITÉ INHIBITRICE CIBLANT TrkA
US20130310379A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
US10150728B2 (en) Alkylene derivatives
US8193352B2 (en) Gyrase inhibitors and uses thereof
US8404852B2 (en) Gyrase inhibitors and uses thereof
US6670367B1 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
US9499533B2 (en) Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
US6440975B1 (en) Amino acid derivatives, the preparation and use thereof as endothelin antagonists
US20150246938A1 (en) Novel olefin derivative
EP2113258A1 (fr) Composition contenant un dérivé de l'aurone pour un diagnostic
US6448248B1 (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
US20170253607A1 (en) Long-acting hiv protease inhibitor
CN101505803B (zh) 用于诊断淀粉样蛋白相关性疾病的组合物
WO2023051261A1 (fr) Composé imine et son utilisation
EP4238960A1 (fr) Dérivé d'amide ayant une activité antivirale
CN101547707A (zh) 包含2-次苯甲基苯并呋喃酮衍生物的诊断用组合物